...
首页> 外文期刊>Molecular Therapy - Methods & Clinical Development >Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy
【24h】

Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy

机译:用于人维斯科特-奥尔德里奇综合征基因治疗的慢病毒载体生产细胞克隆的产生

获取原文

摘要

We have developed a producer cell line that generates lentiviral vector particles of high titer. The vector encodes the Wiskott-Aldrich syndrome (WAS) protein. An insulator element has been added to the long terminal repeats of the integrated vector to limit proto-oncogene activation. The vector provides high-level, stable expression of WAS protein in transduced murine and human hematopoietic cells. We have also developed a monoclonal antibody specific for intracellular WAS protein. This antibody has been used to monitor expression in blood and bone marrow cells after transfer into lineage negative bone marrow cells from WAS mice and in a WAS negative human B-cell line.
机译:我们已经开发了一种生产细胞系,可产生高滴度的慢病毒载体颗粒。该载体编码维斯科特-奥尔德里奇综合症(WAS)蛋白。绝缘子元素已添加到整合载体的长末端重复序列,以限制原癌基因的激活。该载体可在转导的鼠和人造血细胞中高水平,稳定地表达WAS蛋白。我们还开发了一种针对细胞内WAS蛋白的单克隆抗体。在从WAS小鼠转移到谱系阴性骨髓细胞和WAS阴性人B细胞系后,该抗体已用于监测血液和骨髓细胞中的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号